This randomized controlled study have compared trans-arterial chemoembolisation plus sorafenib (157 patients) versus trans-arterial chemoembolisation plus placebo (156 patients) for the treatment of intermediate HCC. Trans-arterial chemoembolisation plus sorafenib failed to improve progression free survival (238 days) compared to trans-arterial chemoembolisation plus placebo (235 days, P value=0.94). Overall survival as well as radiological overall response rate were not different between the two groups.

(Meyer T et al. – Lancet Gastroenterology Hepatology, 22 June 2017)

Read more